Welcome to our dedicated page for Monopar Therapeutics SEC filings (Ticker: MNPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Monopar’s transition from early radiopharmaceutical trials to potential FDA milestones means wading through intricate disclosures. Users regularly ask, “Where can I read the Monopar Therapeutics quarterly earnings report 10-Q filing?” or “How do I monitor Monopar Therapeutics insider trading Form 4 transactions before the market reacts?” If you need Monopar Therapeutics SEC filings explained simply, Stock Titan removes the jargon and highlights what matters in minutes.
Our platform delivers Monopar Therapeutics 8-K material events explained the moment they hit EDGAR, alongside Monopar Therapeutics Form 4 insider transactions real-time alerts that pinpoint every share purchase, option grant, or sale. Interactive dashboards turn each Monopar Therapeutics annual report 10-K simplified into clear talking points and supply concise Monopar Therapeutics earnings report filing analysis that ties R&D spend, cash runway, and trial timelines together—ideal for quick decision making.
Capital raises and clinical risk make management signals essential, so understanding Monopar Therapeutics SEC documents with AI goes further: compare Monopar Therapeutics proxy statement executive compensation to peer norms or spot sentiment shifts via Monopar Therapeutics executive stock transactions Form 4. Whether you’re checking toxicology data for MNPR-101 or gauging partnership amendments, Stock Titan’s AI surfaces every footnote, ratio, and red-flag update without digging through PDFs. Stay current, stay informed, and act confidently.
ONE Gas, Inc. (NYSE: OGS) filed an 8-K disclosing a Regulation FD announcement. The company will release its Q2 2025 financial results after market close on Tuesday, August 5, 2025, and will hold a live conference call on Wednesday, August 6, 2025 at 11 a.m. EDT (10 a.m. CDT). The webcast will be available on the company’s investor-relations website. A news release detailing the call logistics is furnished as Exhibit 99.1. No financial performance metrics, guidance revisions, or other material business developments were included in this filing.
Monopar Therapeutics (MNPR) – Form 4 insider transaction filed for Chief Operating Officer Andrew Cittadine covering activity on 30 June 2025.
- 6,863 common shares were issued to Cittadine upon the vesting of Restricted Stock Units (RSUs) granted on 2 Feb 2022, 1 Feb 2023 and 4 Mar 2025.
- 2,990 shares were withheld for taxes (transaction code “F”), leaving a net 3,873 new shares.
- Cittadine’s direct common-stock holding after the transactions is 45,858 shares; he also retains 43,001 unvested RSUs.
- No open-market purchases or sales occurred; all activity relates to automatic RSU settlement (transaction code “M”).
The filing indicates a routine equity-compensation event rather than a discretionary purchase. While the COO’s ownership stake increases modestly, the economic outlay is zero; therefore, the signal for outside investors is generally neutral.
Monopar Therapeutics Inc. (MNPR) filed an 8-K to disclose the results of its 17 June 2025 Annual Meeting of Stockholders. Of the 6,115,214 shares entitled to vote, 82.6% (5,048,394) were represented in person or by proxy.
- Director elections: All six nominees—including CEO Chandler D. Robinson and Chair Christopher M. Starr—were elected. Support ranged from 78.7% to 99.9% of votes cast, with 655,826 broker non-votes recorded for each nominee.
- Say-on-pay: Executive compensation was approved with 4,382,795 votes for (99.8%), 2,933 against, and 6,840 abstentions.
- Say-on-pay frequency: Shareholders selected an annual advisory vote, receiving 4,383,765 votes, dwarfing biennial (1,247) and triennial (1,212) options.
- Auditor ratification: BPM LLP was ratified as independent accountant for FY-2025 with 5,044,817 votes for (99.9%).
No other matters were submitted. The outcome signals continued shareholder support for current governance, compensation practices, and audit oversight. No immediate financial impact or strategic change was disclosed.
FAQ
What is the current stock price of Monopar Therapeutics (MNPR)?
What is the market cap of Monopar Therapeutics (MNPR)?
What is the core focus of Monopar Therapeutics Inc?
Which technological approach does the company use in its cancer therapeutics?
What products are featured in Monopar's pipeline?
How does Monopar approach research and development?
How does its radiopharmaceutical strategy differentiate Monopar in the market?
What role do strategic collaborations play in Monopar’s operations?
Why is uPAR an important target in Monopar's cancer therapies?
How does Monopar position itself within the competitive landscape of biotechnology?
